Skip to content

Drug Testing and Analysis

ISSN 1942-7603

112 papers in the library · 3,280 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities.

Drug Testing and Analysis March 1, 2023 Pierce V. Kavanagh, Folker Westphal, Benedikt Pulver et al. 7 citations

The development of novel lysergamides continues to occur, based on both the needs of psychedelic medicine and commercial interest in new recreational substances. The present study continues the authors' research on novel lysergamides and describes the analytical profile of 1-cyclopropanoyl-AL-LAD (IUPAC name:...

N,N‐Diformylmescaline: A novel analogue of mescaline detected in Queensland

Drug Testing and Analysis October 17, 2022 Ryan Gallagher, Maddison G. Mclaughlin, Karen Blakey et al. 2 citations

Abstract N,N ‐Diformylmescaline, a novel analogue of mescaline, has recently been detected in Australia in two unrelated seizures. To confirm the identification, a three‐step synthesis from 3,4,5‐trimethoxyphenylacetic acid was devised. However, purification of the final product proved problematic with the compound prone to degradation in solution. Analysis of the compound by LC–MS indicated...

Structure identification and analysis of the suspected chemical precursor of 2-fluorodeschloroketamine and its decomposition products.

Drug Testing and Analysis June 1, 2022 Xuan Luo, Di Zhang, Qiulian Luo et al. 4 citations

In this work, 1-[(2″-fluorophenyl)(methylimino)methyl]cyclopentan-1-ol (2-fluorodeschlorohydroxylimine) was identified as a suspected chemical precursor of 2-fluorodeschloroketamine (2-FDCK) using gas chromatography-mass spectrometry (GC-MS) and gas chromatography-quadrupole/time-of-flight mass spectrometry (GC-Q/TOF-MS) and comparing the data with those of ketamine and its chemical precursor,...

Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P‐AL‐LAD

Drug Testing and Analysis May 7, 2022 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 14 citations

Abstract Lysergic acid diethylamide (LSD) is known to induce powerful psychoactive effects in humans, which cemented its status as an important tool for clinical research. A range of analogues and derivatives has been investigated over the years, including those classified as new psychoactive substances. This study presents the characterization of the novel lysergamide N , N...

Tentative identification of in vitro metabolites of O‐acetylpsilocin (psilacetin, 4‐AcO‐DMT) by UHPLC‐Q‐Orbitrap MS

Drug Testing and Analysis March 21, 2022 Wenya Zhai, Le Li, Junbo Zhao et al. 5 citations

Abstract 4‐Acetoxy‐ N , N ‐dimethyltryptamine (4‐AcO‐DMT, psilacetin, O ‐acetylpsilocin) is a synthetic tryptamine with psychedelic properties. Psilacetin may also act as precursor drug of psilocin, similar to psilocybin, but little is known about its metabolism. In this study, the phase I and phase II in vitro metabolism of 4‐AcO‐DMT was investigated with pooled human liver microsomes, and the...

Metabolite elucidation of 2-fluoro-deschloroketamine (2F-DCK) using molecular networking across three complementary in vitro and in vivo models.

Drug Testing and Analysis 2022 Thomas Gicquel, Romain Pelletier, Camille Richeval et al. 32 citations

This work first aims to investigate metabolites of 2-fluoro-deschloroketamine (2F-DCK), a new arylcyclohexylamine derivatives (a group of dissociative ketamine-based substances) using two in vitro experimental approaches, and to compare obtained results by means of molecular networking. Metabolites of 2F-DCK were investigated using both human liver microsomes (HLMs) and hepatic (HepaRG) cell...

Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1‐valeroyl‐d‐lysergic acid diethylamide (1V‐LSD)

Drug Testing and Analysis November 27, 2021 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 19 citations

Abstract The psychopharmacological properties of the psychedelic drug lysergic acid diethylamide (LSD) have attracted the interest of several generations of scientists. While further explorations involving novel LSD‐type compounds are needed to assess their potential as medicinal drugs, the emergence of novel derivatives as recreational drugs has also been observed. 1‐Valeroyl‐LSD (also known...

Metabolic profiling of deschloro-N-ethyl-ketamine and identification of new target metabolites in urine and hair using human liver microsomes and high-resolution accurate mass spectrometry.

Drug Testing and Analysis June 1, 2021 Islam Amine Larabi, Fanny Zerizer, Alice Ameline et al. 23 citations

The aim of this study was to identify new markers of deschloro-N-ethyl-ketamine (O-PCE), a ketamine analogue that has been involved in acute intoxications with severe outcomes including death and whose metabolism has never been studied before. In vitro study after 2-h incubation with pooled human liver microsomes (HLMs) cross-checked by the analysis of urine and hair from a 43-year-old O-PCE...

Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA

Drug Testing and Analysis May 22, 2021 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 12 citations

Abstract Lysergic acid diethylamide (LSD) is a potent psychoactive substance that has attracted great interest in clinical research. As the pharmacological exploration of LSD analogs continues to grow, some of those analogs have appeared on the street market. Given that LSD analogs are uncontrolled in many jurisdictions, it is important that these analogs be differentiated from LSD. This report...

Kinetic profile of N,N-dimethyltryptamine and β-carbolines in saliva and serum after oral administration of ayahuasca in a religious context.

Drug Testing and Analysis March 1, 2021 Rafael Lanaro, Sueli Moreira Mello, Kelly Francisco da Cunha et al. 10 citations

Ayahuasca is a beverage obtained from Banisteriopsis caapi plus Psychotria viridis. B. caapi contains the β-carbolines harmine, harmaline, and tetrahydroharmine that are monoamine oxidase inhibitors and P. viridis contains N,N-dimethyltryptamine (DMT) that is responsible for the visionary effects of the beverage. Ayahuasca use is becoming a global phenomenon, and the recreational use of DMT and...

Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis

Drug Testing and Analysis October 29, 2020 Klára Gotvaldová, Kateřina Hájková, Jan Borovička et al. 69 citations

Abstract Psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin are tryptamines structurally similar to the neurotransmitter serotonin. Psilocybin and its pharmacologically active metabolite psilocin in particular are known for their psychoactive effects. These substances typically occur in most species of the genus Psilocybe (Fungi, Strophariaceae). Even the sclerotia of some of...

Human hair tests to document drug environmental contamination: Application in a family law case involving N,N-dimethyltryptamine.

Drug Testing and Analysis October 23, 2020 Pascal Kintz, Alice Ameline, J. Raul 10 citations

For 40 years, hair tests have been presented as the best approach to document long-term consumption of a drug. This unique property has found numerous applications in clinical, forensic, and occupational toxicology. However, since the beginning of its implementation in biology, external contamination, with an associated risk of false positive result, has been presented as the key in the final...

Analytical profile of N‐ethyl‐N‐cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4‐dimethylazetidide (LSZ)

Drug Testing and Analysis August 24, 2020 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 5 citations

Recent investigations have shown that N-ethyl-N-cyclopropyl lysergamide (ECPLA) produces LSD-like behavioral effects in mice, which suggests that it may act as a hallucinogen in humans. Although the use of ECPLA as a recreational drug has been limited, key analytical data that can be used to detect ECPLA are required for future forensic and clinical investigations. ECPLA is an isomer of...

Synthesis and characterization of high‐purity N,N‐dimethyltryptamine hemifumarate for human clinical trials

Drug Testing and Analysis July 1, 2020 Nicholas V. Cozzi, Paul F. Daley 12 citations

Abstract Since 2006, there has been a resurgent interest in the pharmacology and therapeutics of psychedelic drugs. Psilocybin, the 4‐phosphoryl ester of N,N ‐dimethyltryptamine (DMT), has been studied most often, but DMT itself is also appealing because of its brief but profound psychological effects and its presence as an endogenous substance in mammalian brain. Although there have been a few...

Pharmacokinetics and subjective effects of 1P‐LSD in humans after oral and intravenous administration

Drug Testing and Analysis May 16, 2020 Christina Grumann, Kerstin Henkel, Simon D. Brandt et al. 23 citations

Abstract 1‐Propanoyl‐lysergic acid diethylamide (1P‐LSD) appeared as a non‐controlled alternative to LSD a few years ago. Although evidence is beginning to emerge from in vitro and animal studies that 1P‐LSD might serve as a prodrug for LSD, an equivalent evaluation in humans is unavailable. Controlled oral and intravenous self‐administrations of 100 μg 1P‐LSD hemitartrate are reported in two...

In vitro and in vivo metabolism and detection of 3-HO-PCP, a synthetic phencyclidine, in human samples and pooled human hepatocytes using high resolution mass spectrometry.

Drug Testing and Analysis April 20, 2020 A. Davidsen, Marie Mardal, Sys S Johansen et al.

The new psychoactive substance (NPS) 3-HO-PCP, a phencyclidine (PCP) analogue, was detected in a law enforcement seizure and in forensic samples in Denmark. Compared to PCP, 3-HO-PCP is known to be a more potent dissociative NPS, but no toxicokinetic investigations of 3-HO-PCP are yet available. Therefore, 3-HO-PCP was quantified in in vivo samples, and the following were investigated: plasma...

Multimodal imaging of hallucinogens 25C- and 25I-NBOMe on blotter papers.

Drug Testing and Analysis April 1, 2020 Elias Lützen, Michael Holtkamp, Imke Stamme et al.

Due to the much lower production costs but similar effects to lysergic acid diethylamide (LSD), phenethylamine derivatives are sold as a cheaper replacement or deceptively as LSD itself. These potent hallucinogenic substances can lead to severe intoxication, thus a more profound understanding of their use is required. This includes the elucidation of the manufacturing processes for the commonly...

Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐d‐lysergic acid diethylamide (1CP‐LSD)

Drug Testing and Analysis March 16, 2020 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 38 citations

Abstract Lysergic acid diethylamide (LSD) is a prototypical serotonergic psychedelic drug and the subject of many clinical investigations. In recent years, a range of lysergamides has emerged with the production of some being inspired by the existing scientific literature. Others, for example various 1‐acyl substituted lysergamides, did not exist before their appearance as research chemicals....

Synthesis and identification of deschloroketamine metabolites in rats' urine and a quantification method for deschloroketamine and metabolites in rats' serum and brain tissue using liquid chromatography tandem mass spectrometry

Drug Testing and Analysis October 31, 2019 Kateřina Hájková, Bronislav Jurásek, Jan Čejka et al. 12 citations

Deschloroketamine (2-(methylamino)-2-phenyl-cyclohexanone) is a ketamine analog belonging to a group of dissociative anesthetics, which have been distributed within the illicit market since 2015. However, it was also being sold as 'ketamine' misleading people to believe that they were getting genuine ketamine. Dissociative anesthetics have also come to the attention of the psychiatric field due...

Phenethylamine-derived new psychoactive substances 2C-E-FLY, 2C-EF-FLY, and 2C-T-7-FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings.

Drug Testing and Analysis October 1, 2019 Lea Wagmann, Nora Hempel, Lilian H. J. Richter et al. 20 citations

Psychoactive substances of the 2C-series are phenethylamine-based designer drugs that can induce psychostimulant and hallucinogenic effects. The so-called 2C-FLY series contains rigidified methoxy groups integrated in a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran core. The aim of the presented work was to investigate the in vivo and in vitro metabolic fate including isoenzyme activities and...

Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD)

Drug Testing and Analysis May 13, 2019 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 72 citations

Abstract The psychedelic properties of lysergic acid diethylamide (LSD) have captured the imagination of researchers for many years and its rediscovery as an important research tool is evidenced by its clinical use within neuroscientific and therapeutic settings. At the same time, a number of novel LSD analogs have recently emerged as recreational drugs, which makes it necessary to study their...

Syntheses and analytical characterizations of the research chemical 1‐[1‐(2‐fluorophenyl)‐2‐phenylethyl]pyrrolidine (fluorolintane) and five of its isomers

Drug Testing and Analysis April 30, 2019 Michael Dybek, Jason Wallach, Pierce V. Kavanagh et al. 9 citations

Abstract A number of substances based on the 1,2‐diarylethylamine template have been investigated for various potential clinical applications whereas others have been encountered as research chemicals sold for non‐medical use. Some of these substances have transpired to function as NMDA receptor antagonists that elicit dissociative effects in people who use these substances recreationally....

Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 – A potential risk to users?

Drug Testing and Analysis April 22, 2019 Lewis Couchman, Anca Frinculescu, Catarina Sobreira et al. 35 citations

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA, Ecstasy) tablets are widely used recreationally, and not only vary in appearance, but also in MDMA content. Recently, the prevalence of high‐content tablets is of concern to public health authorities. To compare UK data with other countries, we evaluated MDMA content of 412 tablets collected from the UK, 2001–2018, and investigated within‐batch...

Pharmacokinetic properties of 4‐fluoroamphetamine in serum and oral fluid after oral ingestion

Drug Testing and Analysis March 26, 2019 Stefan W. Toennes, David J. Schneider, Werner Pogoda et al. 9 citations

INTRODUCTION: Each year, synthetic drugs occur in high numbers on the illicit drug market. But data on their pharmacology and toxicology are scarce. Therefore, a controlled study was performed to evaluate pharmacokinetic parameters of 4-fluoroamphetamine (4-FA) in humans and to compare it with effects. METHODS: Twelve subjects ingested 100 mg and five subjects also received 150 mg 4-FA in a...

Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases.

Drug Testing and Analysis February 1, 2019 Lea Wagmann, Simon D. Brandt, Alexander Stratford et al. 26 citations

Psychoactive substances of the 2C-series (2Cs) are phenethylamine-derived designer drugs that can induce psychostimulant and hallucinogenic effects. Chemically, the classic 2Cs contain two methoxy groups in positions 2 and 5 of the phenyl ring, whereas substances of the so-called FLY series contain rigidified methoxy groups integrated in a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran core. One...